NICE Approves Wegovy for NHS Use, Extending Access to 1.2 Million at-Risk Patients

NICE's approval of Wegovy signifies its endorsement of GLP-1 drugs for cardiovascular risk reduction, opening treatment options to a large population. This decision could influence future NHS drug policies and obesity management strategies. Next, stakeholders will monitor patient outcomes and cost-effectiveness to assess long-term benefits.